-
Je něco špatně v tomto záznamu ?
Long-term efficacy, safety, and tolerability of a subcutaneous immunoglobulin 16.5% (cutaquig®) in the treatment of patients with primary immunodeficiencies
RH. Kobayashi, J. Litzman, I. Melamed, JF. Mandujano, AL. Kobayashi, B. Ritchie, B. Geng, TP. Atkinson, S. Rehman, S. Höller, E. Turpel-Kantor, H. Kreuwel, JC. Speer, S. Gupta
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
NLK
Free Medical Journals
od 1966 do Před 1 rokem
PubMed Central
od 1966 do Před 1 rokem
Medline Complete (EBSCOhost)
od 1966-01-01 do Před 1 rokem
PubMed
36208448
DOI
10.1093/cei/uxac092
Knihovny.cz E-zdroje
- MeSH
- bakteriální infekce * MeSH
- imunoglobulin G terapeutické užití MeSH
- intravenózní imunoglobuliny terapeutické užití MeSH
- lidé MeSH
- prospektivní studie MeSH
- subkutánní infuze MeSH
- syndromy imunologické nedostatečnosti * farmakoterapie MeSH
- výsledek terapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
A prospective study and its long-term extension examined whether weekly treatment of patients with primary immunodeficiencies (PIDs) with a 16.5% subcutaneous immunoglobulin (SCIg; cutaquig®) confers acceptable efficacy, safety, and tolerability over a follow-up of up to 238 weeks (>4 years). Seventy-five patients received 4462 infusions during up to 70 weeks of follow-up in the main study and 27 patients received 2777 infusions during up to 168 weeks of follow-up in the extension. In the main study, there were no serious bacterial infections (SBIs), and the annual rate of other infections was 3.3 (95% CI 2.4, 4.5). One SBI was recorded in the extension, for an SBI rate of 0.02 (upper 99% CI 0.19). The annual rate of all infections over the duration of the extension study was 2.2 (95% CI 1.2, 3.9). Only 15.0% (1085) of 7239 infusions were associated with infusion site reactions (ISRs), leaving 85.0% (6153) of infusions without reactions. The majority of ISRs were mild and transient. ISR incidence decreased over time, from 36.9% to 16% during the main study and from 9% to 2.3% during the extension. The incidence of related systemic adverse events was 14.7% in the main study and 7.4% in the extension. In conclusion, this prospective, long-term study with cutaquig showed maintained efficacy and low rates of local and systemic adverse reactions in PID patients over up to 238 weeks of follow-up.
Allergy and Asthma Center Inc Toledo OH USA
Department of Pediatric Allergy Asthma and Immunology University of Alabama Birmingham AL USA
Division of Basic and Clinical Immunology University of California Irvine Irvine CA USA
Division of Hematology Department of Medicine University of Alberta Hospital Edmonton AB Canada
Divisions of Allergy and Immunology University of California San Diego La Jolla CA USA
IMMUNOe Research Center Centennial CO USA
Midlands Pediatrics Papillion NE USA
Octapharma Pharmazeutika Produktionsges m b H Vienna Austria
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22032168
- 003
- CZ-PrNML
- 005
- 20230131150718.0
- 007
- ta
- 008
- 230120s2022 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1093/cei/uxac092 $2 doi
- 035 __
- $a (PubMed)36208448
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Kobayashi, Roger H $u UCLA School of Medicine, Los Angeles, CA, USA
- 245 10
- $a Long-term efficacy, safety, and tolerability of a subcutaneous immunoglobulin 16.5% (cutaquig®) in the treatment of patients with primary immunodeficiencies / $c RH. Kobayashi, J. Litzman, I. Melamed, JF. Mandujano, AL. Kobayashi, B. Ritchie, B. Geng, TP. Atkinson, S. Rehman, S. Höller, E. Turpel-Kantor, H. Kreuwel, JC. Speer, S. Gupta
- 520 9_
- $a A prospective study and its long-term extension examined whether weekly treatment of patients with primary immunodeficiencies (PIDs) with a 16.5% subcutaneous immunoglobulin (SCIg; cutaquig®) confers acceptable efficacy, safety, and tolerability over a follow-up of up to 238 weeks (>4 years). Seventy-five patients received 4462 infusions during up to 70 weeks of follow-up in the main study and 27 patients received 2777 infusions during up to 168 weeks of follow-up in the extension. In the main study, there were no serious bacterial infections (SBIs), and the annual rate of other infections was 3.3 (95% CI 2.4, 4.5). One SBI was recorded in the extension, for an SBI rate of 0.02 (upper 99% CI 0.19). The annual rate of all infections over the duration of the extension study was 2.2 (95% CI 1.2, 3.9). Only 15.0% (1085) of 7239 infusions were associated with infusion site reactions (ISRs), leaving 85.0% (6153) of infusions without reactions. The majority of ISRs were mild and transient. ISR incidence decreased over time, from 36.9% to 16% during the main study and from 9% to 2.3% during the extension. The incidence of related systemic adverse events was 14.7% in the main study and 7.4% in the extension. In conclusion, this prospective, long-term study with cutaquig showed maintained efficacy and low rates of local and systemic adverse reactions in PID patients over up to 238 weeks of follow-up.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a prospektivní studie $7 D011446
- 650 _2
- $a subkutánní infuze $7 D055104
- 650 12
- $a syndromy imunologické nedostatečnosti $x farmakoterapie $7 D007153
- 650 _2
- $a imunoglobulin G $x terapeutické užití $7 D007074
- 650 12
- $a bakteriální infekce $7 D001424
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a intravenózní imunoglobuliny $x terapeutické užití $7 D016756
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Litzman, Jiří $u Department of Clinical Immunology and Allergology, St Anne's University Hospital in Brno, Faculty of Medicine, Masaryk University, Brno, Czechia
- 700 1_
- $a Melamed, Isaac $u IMMUNOe Research Center, Centennial, CO, USA
- 700 1_
- $a Mandujano, J Fernando $u Pediatric Pulmonary Associates of North Texas, Frisco, TX, USA
- 700 1_
- $a Kobayashi, Ai Lan $u Midlands Pediatrics, Papillion, NE, USA
- 700 1_
- $a Ritchie, Bruce $u Division of Hematology, Department of Medicine, University of Alberta Hospital, Edmonton, AB, Canada
- 700 1_
- $a Geng, Bob $u Divisions of Allergy and Immunology, University of California San Diego, La Jolla, CA, USA
- 700 1_
- $a Atkinson, T Prescott $u Department of Pediatric Allergy, Asthma and Immunology, University of Alabama, Birmingham, AL, USA
- 700 1_
- $a Rehman, Syed $u Allergy and Asthma Center Inc., Toledo, OH, USA
- 700 1_
- $a Höller, Sonja $u Octapharma Pharmazeutika Produktionsges.m.b.H., Vienna, Austria
- 700 1_
- $a Turpel-Kantor, Eva $u Octapharma Pharmazeutika Produktionsges.m.b.H., Vienna, Austria
- 700 1_
- $a Kreuwel, Huub $u Octapharma US, Paramus, NJ, USA
- 700 1_
- $a Speer, J C $u Octapharma US, Paramus, NJ, USA
- 700 1_
- $a Gupta, Sudhir $u Division of Basic and Clinical Immunology, University of California Irvine, Irvine, CA, USA
- 773 0_
- $w MED00009471 $t Clinical and experimental immunology $x 1365-2249 $g Roč. 210, č. 2 (2022), s. 91-103
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36208448 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230120 $b ABA008
- 991 __
- $a 20230131150714 $b ABA008
- 999 __
- $a ok $b bmc $g 1891124 $s 1183503
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2022 $b 210 $c 2 $d 91-103 $e 2022Dec15 $i 1365-2249 $m Clinical and experimental immunology $n Clin Exp Immunol $x MED00009471
- LZP __
- $a Pubmed-20230120
